BCIwiki (bciwiki.com) — According to NeuroXess's announcement dated October 28, 2026, the company has closed a RMB 700 million Series B round co-led by Guotou Juli, Shenzhen Capital Group, and Qinzhi Capital. It also reports participation from other investors and continued support from existing backers.
NeuroXess says the proceeds will support four areas: multicenter registration trials and regulatory approval work for its fully implantable, fully wireless, fully functional ("Three-All") brain-computer interface (BCI) system; manufacturing facility construction; next-generation product development; and exploration of BCI–AI integration. These are planned uses of funds, not evidence that the development, approval, or production objectives have already been met.
On clinical development, the company reports that the Three-All system's GCP registration trial began at Huashan Hospital, Fudan University, on July 7, 2026, with Professor Mao Ying's team serving as principal investigators and nearly 20 tertiary Grade A hospitals across China participating. Starting a registration trial does not mean that the device has received marketing approval.
On manufacturing, NeuroXess says construction of its "super factory" has started, with a planned area of 14,300 square meters and a target production capacity on the scale of 10,000 systems. For next-generation products, it plans further development of language BCIs and advancement of visual BCIs. Its BCI–AI work will explore invoking AI through intent, connecting tools, and controlling the environment. The company targets scaled deployment in the medical market within two years; this remains its stated timeline.